Monitor for BiPASS top-line data readout and NDA submission timeline. The FDA alignment de-risks the regulatory pathway, but approval is not guaranteed. If positive, this could transform Telix's imaging franchise by moving PSMA-PET into the initial diagnostic setting, expanding the patient pool well beyond current staging/recurrence indications.
Price Chart
Executive Summary
Telix completed enrollment (350 patients) in the Phase 3 BiPASS study evaluating Illuccix/Gozellix for pre-biopsy prostate cancer imaging, and aligned with the FDA on an NDA pathway. If successful, this could expand PSMA-PET imaging to a substantially larger patient population (3M biopsies/year globally, up to 75% negative), representing a significant label expansion opportunity for Telix's commercial imaging franchise.
Key Facts
- Phase 3 BiPASS study completed enrollment of 350 patients in the U.S. and Australia
- FDA alignment on NDA pathway for pre-biopsy prostate cancer imaging indication
- Prior PRIMARY/PRIMARY2 studies showed 68Ga-PSMA-PET + MRI can reduce unnecessary biopsies by ~50%
- Globally >3M prostate biopsies/year; up to 75% are negative, representing a large addressable market expansion
- Illuccix and Gozellix are already FDA-approved for staging and recurrence imaging; pre-biopsy would be a new product with separate reimbursement
Financial Impact
No financial data provided; potential to significantly expand addressable patient population for Telix's commercial PSMA-PET imaging agents, but revenue impact contingent on BiPASS data and FDA approval
Risk Factors
- BiPASS may fail to meet primary endpoints (diagnostic accuracy vs. standard of care)
- FDA may require additional data or reject the NDA despite alignment
- Competition from other PSMA-PET agents and alternative diagnostic approaches
- Reimbursement hurdles for new pre-biopsy indication
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3354739 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $12.83 $11.95 | ▼ −6.86% | ▼ −8.99% | $10.55 (−17.77%) |
Sep 14, 2026 18d ago | Press Release | $11.78 $11.31 | ▼ −3.99% | ▼ −4.10% | $10.55 (−10.44%) |
Sep 2, 2026 4w ago | 6-K | $11.45 $11.90 | ▲ +3.93% | ▲ +4.89% | $10.55 (−7.86%) |
Sep 1, 2026 4w ago | Press Release | $11.45 $11.90 | ▲ +3.93% | ▲ +4.89% | $10.55 (−7.86%) |
Aug 20, 2026 6w ago | 6-K | $12.42 $11.38 | ▼ −8.41% | ▼ −9.53% | $10.55 (−15.06%) |
Aug 20, 2026 6w ago | Press Release | $12.42 $11.38 | ▼ −8.41% | ▼ −9.53% | $10.55 (−15.06%) |
Jul 30, 2026 9w ago | Press Release | $9.89 $11.52 | ▲ +16.48% | ▲ +12.97% | $10.55 (+6.67%) |
Jul 21, 2026 10w ago | Press Release | $10.32 $10.10 | ▼ −2.13% | ▲ +0.27% | $10.55 (+2.23%) |
Jul 21, 2026 10w ago | 6-K | $10.92 $9.98 | ▼ −8.61% | ▼ −7.38% | $10.55 (−3.39%) |
Jul 20, 2026 10w ago | Press Release | $10.92 $9.98 | ▼ −8.61% | ▼ −7.38% | $10.55 (−3.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access